Результаты поиска

Crosslink between atrial fibrillation and cancer: a therapeutic conundrum.

Atrial fibrillation (AF) is more common in patients with malignancies than in general population. The pathophysiological processes include the pro-inflammatory condition and the exaggerated inflammatory reaction to chemotherapy, radiotherapy, and surgery interventions. Thus, it is pivotal to decrease morbidity and mortality in this group by providing appropriate care and prevention. In this subset, the risk of thromboembolic and bleeding events is high and the common risk score such as CHA2DS2-VASc and HAS-BLED employed in non-oncologic patients have limited evidence in cancer patients. A pauc

Совпадение в полном тексте источника
… In individuals with a high embolic hazard and conditions that exclude long-term anticoagulation consider percutaneous left atrial appendage closure as a secure and efficacious alternative. … Left atrial appendage closure outcomes in patients with cancer at a single tertiary center. Am J Cardiol. 2023 Jul 11;202:176–181. 10.1016/j.amjcard.2023.06.068. Epub ahead of print. PMID: 37441832. 98. …

Prevalence of Atrial Fibrillation and Intervention Therapy in Cardiac Amyloidosis.

Atrial fibrillation (AF) is a common and serious arrhythmia that frequently complicates cardiac amyloidosis (CA), a rare condition characterized by amyloid deposits in the heart. The coexistence of AF in CA patients significantly increases the risk of heart failure, stroke, and other life-threatening complications; however, the therapeutic approach to managing AF in CA patients remains underexplored. Thus, this review discusses the features of AF in CA patients, recent research on the development of effective treatment options, and strategies for future therapies. A comprehensive review of the

Совпадение в полном тексте источника
… Left atrial appendage closure (LAAC) or left atrial appendage occlusion (LAAO) are traditional interventions to reduce the risk of thrombosis in patients with AF. Recent studies have demonstrated its efficacy in AF with a high risk of bleeding. … Cardiac amyloidosis and left atrial appendage closure. The CAMYLAAC study. Revista Espanola De Cardiologia (English Ed.) . 2023;76:503–510. doi: 10.1016/j.rec.2022.08.001. …

Arrhythmic Risk Stratification in Cardiac Amyloidosis: A Review of the Current Literature.

Cardiac amyloidosis is the most frequent infiltrative disease caused by the deposition of misfolded proteins in the cardiac tissue, leading to heart failure, brady- and tachyarrhythmia and death. Conduction disorders, atrial fibrillation (AF) and ventricular arrhythmia (VA) significantly impact patient outcomes and demand recognition. However, several issues remain unresolved regarding early diagnosis and optimal management. Extreme bradycardia is the most common cause of arrhythmic death, while fast and sustained VAs can be found even in the early phases of the disease. Risk stratification an

Совпадение в полном тексте источника
… Left Atrial Appendage Closure Studies on OAC’s effectiveness in patients with CA are limited and concerns regarding the concomitant higher thrombotic and bleeding risks compared to the general population need to be considered [ 98 , 100 , 101 ]. … Cardiac amyloidosis and left atrial appendage closure. The CAMYLAAC study Rev. Esp. Cardiol. 2023 76 503 510 10.1016/j.recesp.2022.07.011 35934294 105. Santarone M. Corrado G. Tagliagambe L.M. Manzillo G.F. Tadeo G. Spata M. Longhi M. …

Dual Antiplatelet Therapy and Cancer; Balancing between Ischemic and Bleeding Risk: A Narrative Review.

Cardiovascular (CV) events in patients with cancer can be caused by concomitant CV risk factors, cancer itself, and anticancer therapy. Since malignancy can dysregulate the hemostatic system, predisposing cancer patients to both thrombosis and hemorrhage, the administration of dual antiplatelet therapy (DAPT) to patients with cancer who suffer from acute coronary syndrome (ACS) or undergo percutaneous coronary intervention (PCI) is a clinical challenge to cardiologists. Apart from PCI and ACS, other structural interventions, such as TAVR, PFO-ASD closure, and LAA occlusion, and non-cardiac dis

Совпадение в полном тексте источника
… Keller K. 5-Year Experience of In-Hospital Outcomes After Percutaneous Left Atrial Appendage Closure in Germany JACC. Cardiovasc. Interv. 2019 12 1044 1052 10.1016/j.jcin.2019.04.002 31171280 98. Chen S. Weise F.K. Chun K.R.J. Schmidt B. … Initial and long-term antithrombotic therapy after left atrial appendage closure with the WATCHMAN Europace 2020 22 1036 1043 10.1093/europace/euaa074 32464648 100. Patti G. Sticchi A. Verolino G. Pasceri V. Vizzi V. Brscic E. Casu G. Golino P. Russo V. Rapacciuolo A. …

EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer.

In cancer patients, thrombocytopenia can result from bone marrow infiltration or from anticancer medications and represents an important limitation for the use of antithrombotic treatments, including anticoagulant, antiplatelet, and fibrinolytic agents. These drugs are often required for prevention or treatment of cancer-associated thrombosis or for cardioembolic prevention in atrial fibrillation in an increasingly older cancer population. Data indicate that cancer remains an independent risk factor for thrombosis even in case of thrombocytopenia, since mild-to-moderate thrombocytopenia does n

Standard Poster Abstracts for the 17th Asia Pacific Heart Rhythm Society (APHRS) Scientific Sessions

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstract

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Current Data and Future Perspectives on Patients with Atrial Fibrillation and Cancer

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Procedural and Short-Term Outcomes of Percutaneous Left Atrial Appendage Closure in Patients with Cancer. Am. J. Cardiol. 2021;141:154–157. doi: 10.1016/j.amjcard.2020.12.003. 67. Peixoto de Miranda É.J.F., Takahashi T., Iwamoto F., Yamashiro S., Samano E., Macedo A.V.S., Ramacciotti E. …

Best of JACC: Case Reports From ACC.23.

This dedicated issue of JACC: Case Reports highlights the top ranked Complex Clinical Cases from the ACC 2023 Scientific Sessions. These cases were reviewed and selected by a committee of peers in the months leading up to the annual meeting. These reviewers were ACC members with no affiliation to the JACC: Case Reports Editorial Board. While the cases were presented at the meeting and included in the formal Abstract Book from ACC, they have not been published elsewhere. These cases illustrate how the ACC can be a place for cardiovascular professionals to come together to learn, grow, and share

Совпадение в полном тексте источника
… Both patients underwent septal myectomy, debridement of MAC, AVR with #25 CE valve and left atrial appendage closure. In addition Patient A underwent chordal sparing MVR with # 29 Biocor valve and ascending aortic aneurysm replacement. …

Cardiac Amyloidosis: Tribulations and New Frontiers.

This review article aims to provide an overview of the pathophysiology, diagnosis, and contemporary management of cardiac amyloidosis (CA) as well as identify the knowledge gaps and areas of potential research. CA can be divided into two main groups: transthyretin cardiac amyloidosis (ATTR-CA) and light chain cardiac amyloidosis (AL-CA). The former further separates into wild-type transthyretin (ATTRwt) and hereditary transthyretin (ATTRv). African Americans, males, and people older than 75 are the most common demographics affected by this disease. Thanks to an increased understanding of this

Резюме ESPR 2013Европейское общество педиатрической радиологии 50th Ежегодное совещание и 36th Курсы для аспирантов. Июнь 3–7 2013. Будапешт, Венгрия.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstracts from the World Congress of Cardiology/Brazilian Congress of Cardiology 2022

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Skin Telocytes Could Fundament the Cellular Mechanisms of Wound Healing in Platelet-Rich Plasma Administration.

For more than 40 years, autologous platelet concentrates have been used in clinical medicine. Since the first formula used, namely platelet-rich plasma (PRP), other platelet concentrates have been experimented with, including platelet-rich fibrin and concentrated growth factor. Platelet concentrates have three standard characteristics: they act as scaffolds, they serve as a source of growth factors and cytokines, and they contain live cells. PRP has become extensively used in regenerative medicine for the successful treatment of a variety of clinical (non-)dermatological conditions like alopec

RESEARCH COMMUNICATIONS OF THE 28th ECVIM-CA CONGRESS.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Emergency Care

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

C

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Р

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstracts from the 37th Annual Meeting of the Society of General Internal Medicine, 2014, San Diego, CA, USA.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

СРП 2013

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Артериальный тромбоэмболизм

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.